Logo
DeutschClear Cookie - decide language by browser settings
Tüxen-Mengedoht, Martina (2006): Fischöltherapie bei Mukoviszidose: Ergebnisse einer randomisierten klinischen Studie. Dissertation, LMU München: Faculty of Medicine
[img]
Preview
PDF
Tuexen-Mengedoht_Martina.pdf

1016Kb

Abstract

Rationale: Chronic inflammation induces progressive pulmonary destruction in CF. In previous in vitro studies we found n-3 fatty acids to effectively suppress the secretion of proinflammatory 5-lipoxygenase products from CF neutrophils (Eur J Clin Invest 1995;25:915-9). Hence, we studied the clinical effects of long-term fish oil treatment in CF. Method: In a double blind, randomised multicenter trial, 69 CF patients aged 7-34 years were assigned to fish oil capsules (F, 36 mg long chain n-3/kg&d; n=35, mean age 13.6 y)or corn oil (P; n=35, 14.8 y) for 12 months and followed for 15 months. Clinical and biochemical data were monitored at 3monthly visits. Results: Mean plasma phospholipid eicosapentaenoic acid increased from 0.9% to 2.8% in F (p<0.05) but not in P. There were no treatment associated changes of weight, length, disease score, infections and urinary leukotriene 4 excretion. Forced vital capacity tended to decrease in P but increased from 79+2.9% of normal to 85+2.8% in F (p=0.04). Serious adverse effects were not observed. Conclusion: Long-term supplementation of fish oil capsules in CF patients is free of serious adverse effects and improves forced vital capacity.